Download MendeleyType III CRISPR-Cas provides resistance against nucleus-forming jumbo phages via abortive infection.
Mayo-Munoz, D., Smith, L.M., Garcia-Doval, C., Malone, L.M., Harding, K.R., Jackson, S.A., Hampton, H.G., Fagerlund, R.D., Gumy, L.F., Fineran, P.C.(2022) Mol Cell 82: 4471-4486.e9
- PubMed: 36395770
- DOI: https://doi.org/10.1016/j.molcel.2022.10.028
- Primary Citation of Related Structures:
7ZGV, 7ZGW - PubMed Abstract:
Bacteria have diverse defenses against phages. In response, jumbo phages evade multiple DNA-targeting defenses by protecting their DNA inside a nucleus-like structure. We previously demonstrated that RNA-targeting type III CRISPR-Cas systems provide jumbo phage immunity by recognizing viral mRNA exported from the nucleus for translation. Here, we demonstrate that recognition of phage mRNA by the type III system activates a cyclic triadenylate-dependent accessory nuclease, NucC. Although unable to access phage DNA in the nucleus, NucC degrades the bacterial chromosome, triggers cell death, and disrupts phage replication and maturation. Hence, type-III-mediated jumbo phage immunity occurs via abortive infection, with suppression of the viral epidemic protecting the population. We further show that type III systems targeting jumbo phages have diverse accessory nucleases, including RNases that provide immunity. Our study demonstrates how type III CRISPR-Cas systems overcome the inaccessibility of jumbo phage DNA to provide robust immunity.
Organizational Affiliation:
Department of Microbiology and Immunology, University of Otago, P.O. Box 56, Dunedin 9054, New Zealand; Genetics Otago, University of Otago, P.O. Box 56, Dunedin 9054, New Zealand; Maurice Wilkins Centre for Molecular Biodiscovery, University of Otago, P.O. Box 56, Dunedin 9054, New Zealand.
